PRODUCT INFORMATION

3-Deazaneplanocin A (hydrochloride)

Item No. 11102

CAS Registry No.: 120964-45-6
Formal Name: 5R-(4-amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)-3-cyclopentene-1S,2R-diol, monohydrochloride
Synonym: 2,3-DMMC
MF: $C_{12}H_{14}N_4O_3 \bullet HCl$
FW: 298.7
Purity: ≥98%
UV/Vis.: λ_{max}: 216, 267 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

3-Deazaneplanocin A (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the 3-deazaneplanocin A (hydrochloride) in the solvent of choice, which should be purged with an inert gas. 3-Deazaneplanocin A (hydrochloride) is soluble in the organic solvent DMSO at a concentration of approximately 3 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of 3-deazaneplanocin A (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of 3-deazaneplanocin A (hydrochloride) in PBS (pH 7.2) is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

The lysine methyltransferase EZH2 (KMT6), part of the polycomb repressive complex 2, catalyzes trimethylation of lysine 27 on histone H3 and is involved in proliferation and aggressive cell growth associated with neoplastic cells.[1] 3-Deazaneplanocin A is a cyclopentenyl analog of 3-deazaadenosine, originally synthesized as an inhibitor of S-adenosyl-L-homocysteine hydrolase.[2] It has been shown to deplete EZH2 levels and to inhibit trimethylation of lysine 27 on histone H3 in cultured human acute myeloid leukemia (AML) HL-60 and OCI-AML3 cells and in primary AML cells in a dose-dependent manner (0.2-1 µM).[3] 3-Deazaneplanocin A treatment of cultured human AML cells induces increased expression of the cell-cycle regulators p21, p27, and FBXO32, leading to cell cycle arrest and apoptosis.[3] When used in combination with the pan-histone deacetylase inhibitor panobinostat (10 mg/kg), 3-deazaneplanocin A's (1 mg/kg) antileukemic effects are synergistically enhanced in mice implanted with AML cells.[3,4]

References

1. Simon, J.A. and Lange, C.A. *Mutat. Res.* **647(1-2)**, 21-29 (2008).
2. Tseng, C.K.H., Marquez, V.E., Fuller, R.W., *et al. J. Med. Chem.* **32(7)**, 1442-1446 (1989).
3. Fiskus, W., Wang, Y., Sreekumar, A., *et al. Blood* **114(13)**, 2733-2743 (2009).
4. Bissinger, E.M., Heinke, R., Sippl, W., *et al.* Targeting epigenetic modifiers: Inhibitors of histone methyltransferases. *Med. Chem. Commun.* **1(2)**, (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM